ABHD5 and neoplasm: In the outcome analysis, the patients with ABHD5lowDPY30high c-Methigh tumours had poorer disease-free survival (DFS) than those with ABHD5highDPY30low c-Metlow tumours (Fig. 7c), suggesting the potential value of ABHD5-DPY30- c-Met expression in predicting the prognosis of CRCs.